A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Trial Profile

A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATEMPT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 May 2015 Planned End Date changed to 1 May 2017, according to to ClinicalTrials.gov record.
    • 11 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2017, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top